342 related articles for article (PubMed ID: 24305711)
1. The rationale for targeted therapies in medulloblastoma.
MacDonald TJ; Aguilera D; Castellino RC
Neuro Oncol; 2014 Jan; 16(1):9-20. PubMed ID: 24305711
[TBL] [Abstract][Full Text] [Related]
2. Restore the brake on tumor progression.
Gordon RE; Zhang L; Yang ZJ
Biochem Pharmacol; 2017 Aug; 138():1-6. PubMed ID: 28389227
[TBL] [Abstract][Full Text] [Related]
3. Medulloblastoma: Molecular understanding, treatment evolution, and new developments.
Liu X; Ding C; Tan W; Zhang A
Pharmacol Ther; 2020 Jun; 210():107516. PubMed ID: 32105673
[TBL] [Abstract][Full Text] [Related]
4. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
Li Y; Song Q; Day BW
Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
[TBL] [Abstract][Full Text] [Related]
5. The SHH/GLI signaling pathway: a therapeutic target for medulloblastoma.
Lospinoso Severini L; Ghirga F; Bufalieri F; Quaglio D; Infante P; Di Marcotullio L
Expert Opin Ther Targets; 2020 Nov; 24(11):1159-1181. PubMed ID: 32990091
[TBL] [Abstract][Full Text] [Related]
6. Signaling pathway and molecular subgroups of medulloblastoma.
Li KK; Lau KM; Ng HK
Int J Clin Exp Pathol; 2013; 6(7):1211-22. PubMed ID: 23826403
[TBL] [Abstract][Full Text] [Related]
7. Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma.
Genovesi LA; Millar A; Tolson E; Singleton M; Hassall E; Kojic M; Brighi C; Girard E; Andradas C; Kuchibhotla M; Bhuva DD; Endersby R; Gottardo NG; Bernard A; Adolphe C; Olson JM; Taylor MD; Davis MJ; Wainwright BJ
Genome Med; 2021 Jun; 13(1):103. PubMed ID: 34154646
[TBL] [Abstract][Full Text] [Related]
8. A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.
Pak E; MacKenzie EL; Zhao X; Pazyra-Murphy MF; Park PMC; Wu L; Shaw DL; Addleson EC; Cayer SS; Lopez BG; Agar NYR; Rubin LL; Qi J; Merk DJ; Segal RA
Neuro Oncol; 2019 Sep; 21(9):1150-1163. PubMed ID: 31111916
[TBL] [Abstract][Full Text] [Related]
9. Medulloblastoma drugs in development: Current leads, trials and drawbacks.
Wen J; Hadden MK
Eur J Med Chem; 2021 Apr; 215():113268. PubMed ID: 33636537
[TBL] [Abstract][Full Text] [Related]
10. SHH inhibitors for the treatment of medulloblastoma.
Samkari A; White J; Packer R
Expert Rev Neurother; 2015; 15(7):763-70. PubMed ID: 26027634
[TBL] [Abstract][Full Text] [Related]
11. Targeted treatment for sonic hedgehog-dependent medulloblastoma.
Kieran MW
Neuro Oncol; 2014 Aug; 16(8):1037-47. PubMed ID: 24951114
[TBL] [Abstract][Full Text] [Related]
12. CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway.
Chen J; Lv H; Hu J; Ji M; Xue N; Li C; Ma S; Zhou Q; Lin B; Li Y; Yu S; Chen X
Cancer Lett; 2016 Oct; 381(2):391-403. PubMed ID: 27495899
[TBL] [Abstract][Full Text] [Related]
13. Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma.
Faria CC; Golbourn BJ; Dubuc AM; Remke M; Diaz RJ; Agnihotri S; Luck A; Sabha N; Olsen S; Wu X; Garzia L; Ramaswamy V; Mack SC; Wang X; Leadley M; Reynaud D; Ermini L; Post M; Northcott PA; Pfister SM; Croul SE; Kool M; Korshunov A; Smith CA; Taylor MD; Rutka JT
Cancer Res; 2015 Jan; 75(1):134-46. PubMed ID: 25391241
[TBL] [Abstract][Full Text] [Related]
14. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449.
Rudin CM; Hann CL; Laterra J; Yauch RL; Callahan CA; Fu L; Holcomb T; Stinson J; Gould SE; Coleman B; LoRusso PM; Von Hoff DD; de Sauvage FJ; Low JA
N Engl J Med; 2009 Sep; 361(12):1173-8. PubMed ID: 19726761
[TBL] [Abstract][Full Text] [Related]
15. Statins Synergize with Hedgehog Pathway Inhibitors for Treatment of Medulloblastoma.
Gordon RE; Zhang L; Peri S; Kuo YM; Du F; Egleston BL; Ng JMY; Andrews AJ; Astsaturov I; Curran T; Yang ZJ
Clin Cancer Res; 2018 Mar; 24(6):1375-1388. PubMed ID: 29437795
[No Abstract] [Full Text] [Related]
16. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
Singh AR; Joshi S; Zulcic M; Alcaraz M; Garlich JR; Morales GA; Cho YJ; Bao L; Levy ML; Newbury R; Malicki D; Messer K; Crawford J; Durden DL
PLoS One; 2016; 11(3):e0150836. PubMed ID: 26938241
[TBL] [Abstract][Full Text] [Related]
17. IDO1 involvement in mTOR pathway: a molecular mechanism of resistance to mTOR targeting in medulloblastoma.
Folgiero V; Miele E; Carai A; Ferretti E; Alfano V; Po A; Bertaina V; Goffredo BM; Benedetti MC; Camassei FD; Cacchione A; Locatelli F; Mastronuzzi A
Oncotarget; 2016 Aug; 7(33):52900-52911. PubMed ID: 27174915
[TBL] [Abstract][Full Text] [Related]
18. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma.
Purzner T; Purzner J; Buckstaff T; Cozza G; Gholamin S; Rusert JM; Hartl TA; Sanders J; Conley N; Ge X; Langan M; Ramaswamy V; Ellis L; Litzenburger U; Bolin S; Theruvath J; Nitta R; Qi L; Li XN; Li G; Taylor MD; Wechsler-Reya RJ; Pinna LA; Cho YJ; Fuller MT; Elias JE; Scott MP
Sci Signal; 2018 Sep; 11(547):. PubMed ID: 30206138
[TBL] [Abstract][Full Text] [Related]
19. Targeting AKT and CK2 represents a novel therapeutic strategy for SMO constitutive activation-driven medulloblastoma.
Yao YL; Wang YX; Yang FC; Wang C; Mao M; Gai QJ; He J; Qin Y; Yao XX; Lan X; Zhu J; Lu HM; Zeng H; Yao XH; Bian XW; Wang Y
CNS Neurosci Ther; 2022 Jul; 28(7):1033-1044. PubMed ID: 35419951
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma.
Rodriguez-Blanco J; Pednekar L; Penas C; Li B; Martin V; Long J; Lee E; Weiss WA; Rodriguez C; Mehrdad N; Nguyen DM; Ayad NG; Rai P; Capobianco AJ; Robbins DJ
Oncogene; 2017 Nov; 36(45):6306-6314. PubMed ID: 28714964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
